It gives the most comprehensive view of the fetal genome, covering all 23 pairs of chromosomes. It determines the risk of  more than 430 deletion and duplication syndromes of at least 7 Mb, for all autosomal chromosomes. This resolution is similar to the karyotype from the amniotic fluid (after amniocentesis).

Genome-wide screening
Detects trisomies and monosomies of all the 23 pairs of chromosomes
Screens for more than 430 deletion and duplication syndromes
Maximum TAT (turnaround time) of 5 business days
The only test that determines a risk of all deletion and duplication syndromes covering at least 7 million base pairs
The widest range of a NIPT test for twin pregnancies (genome-wide mode available)
Identifies a risk of genetic abnormalities that cause a miscarriage
Determines a risk of genetic conditions that cause pre-eclampsia, IUGR and low birth weight
Determines a risk of a uniprenatal disomy
Enables early cancer detection

How does the SANCO test work?

Particles of cell-free DNA (cfDNA) are small pieces of DNA that circulate in blood. During pregnancy, DNA fragments from both mother and fetus are present in the bloodstream of the pregnant woman.Cell-free DNA from the fetus (cffDNA) is present only as a minority fraction in the maternal plasma, which is a technical challenge for some of NIPT (Non-invasive Prenatal Test) methods. SANCO Prenatal Test requires a small volume of pregnant blood (10ml) in which cffDNA is analysed to determine a risk of the chromosomal abnormalities. If an aneuploidy is present, the imbalance in the fetal genome will be detected during the test, resulting from an excess or deficiency of chromosomes. SANCO NIPT Test successfully resolves the problem of measuring small differences in the concentration of chromosomal DNA, using a high-throughput sequencing technology. It means that millions of maternal and fetal DNA fragments are sequenced during the test.

Using the genomic sequencing technology, along with an accurate cfDNA molecule length estimation and patented bioinformatics analysis algorithms, SANCO is able to analyse data from the entire fetal genome and, by comparing the measurement results to the fetal fraction, detect the presence of genetic abnormalities.


10 ml of venous blood is collected. The procedure is comparable to taking blood for morphological testing. However, the test tube differs (it has a camo plug), because the blood cells have to be protected against disintegration and contamination of the cell-free DNA. The analysis itself requires 10 ml of blood sample. Fasting before the test is not necessary, however, just as before every blood draw, it’s advisable to drink more water

Patients interested in performing the SANCO test, please select the facility from the list, contact the helpdesk on: +48 797 660 690 or email: This email address is being protected from spambots. You need JavaScript enabled to view it..


The patient's blood is transported to Genomed S.A. in Warsaw. Since May 2015, Genomed S.A. has been the only laboratory in Poland performing non-invasive genetic prenatal testing in its own laboratory in Poland. That is why the SANCO test is the fastest NIPT test available all over the country.

Genomed S.A. participates successfully in the EMQN - European Molecular Quality Network - quality control in the field of non-invasive, prenatal genetic testing and is a laboratory recommended by the Polish Society of Human Genetics. The SANCO test is based on proven and accurate sequencing technology from Illumina, the world leader in next-generation sequencing. The test has a CE IVD certificate.

Genomed S.A. supports patients in further prenatal diagnostics.

Support for the diagnostic process and genetic counselling in justified cases
Refund of invasive tests expenses
Till 2020 Genomed has performed over 30,000 NIPT tests on site
IVDR, CE IVD and EMQN certificates